What is an acceptable false negative rate in the detection of prostate cancer?
Authors:
- the ERSPC Rotterdam study groupTGthe ERSPC Rotterdam study group
- Jan F. M. VerbeekJVJan F. M. Verbeek
Open Access
- 1 February 2018
- journal article
- research article
- Published by AME Publishing Company in Translational Andrology and Urology
- Vol. 7 (1) , 54-60
Abstract
Background: In prostate cancer (PCa) screening men and their physicians aim to rule out the presence of potentially life threatening PCa. To date, prostate specific antigen (PSA) testing and systematic prostate biopsy (Bx)—in case of an elevated PSA—are still the main modes of PCa detection. Often uncertainty remains when a PSA-test is Methods: Our study population consisted of 19,970 men from the ERSPC project section Rotterdam, initially screened in 1993–1999. We assessed clinically significant Gleason ≥3+4 PCa (csPCa) diagnosis within the 4-year screening interval and subsequent screening round 4 years later in men having a PSA 3.0 ng/mL), but no PCa detected at that time. In addition, we addressed PCa mortality and PCa diagnosis for men with a negative PSA test and negative Bx, who were retested every 4 years covering a 15-year follow-up. Results: A total of 14,935 men had PSA Conclusions: The false negative rates for men with PSA <3.0 ng/mL and negative sextant Bx are extremely low but not negligible. Proper risk stratification before deciding to biopsy is expected to hardly miss any clinical significant PCa diagnosis. This is especially relevant with the increased use of the relatively expensive multi-parametric magnetic resonance imaging (mpMRI) guided targeted Bx procedures.Keywords
This publication has 22 references indexed in Scilit:
- What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines PanelEuropean Urology, 2017
- Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory studyThe Lancet, 2017
- Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging ScansEuropean Urology, 2016
- The Diagnostic Performance of Multiparametric Magnetic Resonance Imaging to Detect Significant Prostate CancerJournal of Urology, 2016
- Magnetic Resonance Imaging–targeted Biopsy May Enhance the Diagnostic Accuracy of Significant Prostate Cancer Detection Compared to Standard Transrectal Ultrasound-guided Biopsy: A Systematic Review and Meta-analysisEuropean Urology, 2015
- Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: A randomized studyUrologic Oncology: Seminars and Original Investigations, 2015
- Prospective Evaluation of an Extended 21-Core Biopsy Scheme as Initial Prostate Cancer Diagnostic StrategyEuropean Urology, 2014
- Positive predictive value of prostate biopsy indicated by prostate‐specific‐antigen‐based prostate cancer screening: trends over time in a European randomized trial*BJU International, 2012
- Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging‐targeted and systematic biopsy for significant prostate cancer detectionBJU International, 2011
- Importance of Additional “Extreme” Anterior Apical Needle Biopsies in the Initial Detection of Prostate CancerUrology, 2010